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The crystal structure of a cardiac calsequestrin filament reveals an atomic mechanism
of calsequestrin-associated catecholaminergic polymorphic ventricular tachycardia
Erron Wilcox Titus
Abstract
Calcium homeostasis is essential to cardiac and skeletal muscle physiology, where contractile
function requires tight but dynamic control of calcium levels across different cellular compart-
ments. The major calcium storage protein in muscle tissues is calsequestrin, a highly acidic
protein responsible for buffering up to 50 % of total sarcoplasmic reticulum (SR) calcium. Mu-
tations in cardiac calsequestrin cause a highly lethal familial arrhythmia, catecholaminergic
polymorphic ventricular tachycardia (CPVT), while mutations in skeletal muscle calsequestrin
have been linked to myopathies. Calsequestrin’s high density calcium storage is facilitated
by homomultimerization of the protein into filaments, but a compelling atomic-resolution struc-
ture of a calsequestrin filament is lacking. This gap in knowledge has limited our under-
standing of calsequestrin biochemistry, SR calcium storage, and molecular mechanisms of
calseqestrin-associated diseases. We report here a crystal structure of a cardiac calse-
questrin filament with supporting mutation analysis by an in vitro filamentation assay. We
also report and characterize a novel disease-associated mutation, S173I, which localizes to
the structure’s filament-forming interface. In addition, we show that a previously reported
dominant calsequestrin-associated CPVT mutation, K180R, maps to the same multimeriza-
tion surface. Both mutations disrupt filamentation in vitro, suggesting a model where dominant
disease arises from mutations that disrupt multimer formation. Finally, a ytterbium-derivatized
structure pinpoints multiple credible calcium sites at filament-forming interfaces, explaining
the atomic basis of calsequestrin filamentation in the presence of calcium. This work ad-
vances our basic understanding of calsequestrin biochemistry and also provides a unifying
structure-function molecular mechanism by which dominant-acting calsequestrin mutations
provoke lethal arrhythmias.
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Introduction
The Ca2+ ion is a ubiquitous chemical messenger in eukaryotic cells. Passive flows of calcium
from regions of high concentration to low produce transient changes in intracellular calcium,
which are then coupled to a diverse set of signal transduction pathways. In facilitation of
its diverse roles as an intracellular messenger, calcium exhibits by far the largest concen-
tration difference across compartments, from approximately 2 mM extracellularly to 100 nM
intracellularly - a range of up to 5 orders of magnitude.[1] This calcium gradient exists across
the plasma membrane separating the cytosol from the extracellular space but also between
the cytosol and the endoplasmic reticulum (ER) lumen, with the latter maintaining an ionic
milieu resembling extracellular conditions. Direct physical coupling between the ER lumen
and the extracellular space allows some degree of passive equilibration between these two
compartments[2], so that the biochemical work of establishing and maintaining the potential is
not done twice.
In muscle, the transduction of an electrical signal at the membrane into a calcium flow
that activates the contractile apparatus is known as excitation-contraction coupling. Under
conditions of high muscle loading, the calcium flows required by the contractile apparatus
become much more substantial than other biological calcium fluxes. In order to minimize the
energy expended per contractile cycle, muscle cells possess enhanced calcium buffering at
the sites of storage and release, allowing a high total calcium content with much lower free
calcium. Calsequestrin (CSQ) is a 44 kD highly acidic protein that serves as the principal
calcium buffer of the sarcoplasmic reticulum (SR, a muscle-specific extension of the ER) in
cardiac and skeletal muscle, storing up to 50 % of SR calcium in a bound state, with each
calsequestrin monomer storing up to 40-50 calcium ions.[3][4][5][6][7][8][9] Calsequestrin is
complexed to the SR calcium channel, the ryanodine receptor (RyR), thereby ensuring that
calcium is stored at the site of its release.[10]
Since their initial identification, in 1971, a substantial field of research has formed around
calsequestrins. Calsequestrins (CASQ1 in skeletal muscle and CASQ2 in cardiac muscle)
are highly homologous in structure and function, and 64 % identical in sequence, with skeletal
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muscle calsequestrin appearing to have higher calcium capacity.[11] Calcium-binding propen-
sity is explained in large part by calsequestrin’s remarkable fraction of negatively-charged
acidic residues (26 % glutamate or aspartate in CASQ2 and 28 % in CASQ1, with correspond-
ing average isoelectric points of 4.2 and 4.0, respectively). In both cardiac and skeletal mus-
cle, calsequestrin localizes to the junctional SR (jSR) of muscle and forms multimers that
are anchored to the luminal SR membrane. From low resolution electron micrographs of iso-
lated skeletal muscle fibers, these multimers appear as a dense collection of filaments.[7][12]
Anchoring of calsequestrin filaments occurs within a complex consisting of RyR and the
single-pass transmembrane proteins triadin and junctin.[10] Extended homo-multimerization
provides high density calcium storage, but multimerization appears to be essential for localiza-
tion, too, in that multimerization-defective mutants are trafficked along the secretory pathway
and lost from the ER/SR.[13][14][15] Additional insights into calsequestrin biochemistry and
cell biology encompass post-translational modifications[16][17], calcium-storage capacity[11],
and interactions with the calcium release unit.[18][19][20]. Finally, as our understanding
of calsequestrin biology has advanced, so has our understanding of its role in human dis-
ease. Mutations in skeletal muscle calsequestrin have been putatively linked to malignant
hyperthermia and to vacuolar myopathies[21], while mutations in cardiac calsequestrin are
well known to cause catecholaminergic polymorphic ventricular tachycardia (CPVT), a highly
lethal familial arrhythmia. CPVT is caused by a state of cardiac calsequestrin deficiency,
whether arising from null/hypomorphic alleles or from point mutants that disrupt calsequestrin
multimerization.[22][23] Consistent with a mechanism where by deficiency leads to disease,
most calsequestrin-associated CPVT mutations have recessive inheritance. For a protein
whose function depends on multimerization, there is, at least to date, a surprising paucity of
mutations with putative dominant negative mechanism.
Despite the rich body of work concerning the calsequestrin biology, no compelling high-
resolution candidate structure for a calsequestrin filament has emerged. Although sixteen
crystal structures of calsequestrin have been published[8][11][24][16][25][21][26], none of these
contain a filament-like assembly. All 16 prior structures reveal calsequestrin dimers that are
nearly-identical to one another, but a search for dimer-to-dimer interfaces within and across
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these crystal unit cells reveals only weak crystallographic packing contacts that appear incom-
patible with robust biological multimerization. In addition, the observed dimer-to-dimer inter-
faces vary substantially from one lattice to another. Lack of mutagenesis studies supporting
proposed oligomerization interfaces in the prior published structures further calls into question
whether the relevant biological multimer has ever been observed. These prior studies have
established that calsequestrins dimerize in a wide variety of conditions, with intra-dimer inter-
actions that are largely the same across published structures, but the mechanism by which
dimers assemble into higher order multimers (inter -dimer assembly) remains elusive.
A structure of a calsequestrin filament would advance our understanding of calsequestrin
biology and permit a comprehensive mapping of disease-causing mutations to biologically-
relevant multimerization interfaces. We report here an investigation of dominant-acting car-
diac calsequestrin disease mutants that culminated in a new X-ray structure of cardiac calse-
questrin, one that we believe reveals the biologically relevant filament-forming interface. We
show that known dominant-acting mutants - one previously reported and one described for
the first time in this study - map to the newly reported multimerization interface. Furthermore,
we provide supporting biochemical analysis of likely calcium-binding sites where the protein
multimerizes. These findings fundamentally advance our understanding of the mechanism by
which calsequestrin contributes to calcium homeostasis and provide insight into mechanisms
of calsequestrin-associated familial diseases.
Results
Autosomal Dominant CASQ2 Disease Mutations Disrupt Calsequestrin Multi-
merization
We encountered a proband from a family with CPVT-like tachy-arrhythmias and multiple cases
of sudden, unexplained death at a young age (Figure 1A). The proband presented at age 33
with a biventricular tachycardia on ECG. She underwent EP study that showed an inducible
ventricular tachycardia with focal origination next to the anterior fascicle, and an inducible
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atypical AVNRT that was successfully ablated. Targeted sequencing of channelopathy genes
(KCNQ1, KCNH2, SCN5A, ANK2, KCNE1, KCNE2, KNCJ2, CAV3, RYR2, and CASQ2) re-
vealed only a heterozygously-carried isoleucine-for-serine substitution at position 173 in car-
diac calsequestrin. The proband’s son and multiple other family members report a tachycardic
phenotype (ranging from self-reported palpitations to diagnosed episodes of tachycardia). The
family history is also notable for multiple cases of sudden cardiac death at a young age. Over-
all, the distribution of affected individuals in the pedigree is potentially consistent with dominant
inheritance. As the family did not consent to follow-up genetic testing or clinical phenotyping,
we were unable to rigorously assess disease/mutation co-segregation.
The genetic evidence for pathogenicity of the S173I novel variant is not conclusive, but
since known pathogenic point mutations in CASQ2 exhibit defective filamentation in a simple
turbidity assay, we elected to investigate the S173I mutation biochemically. The turbidity assay
for S173I reveals a profound decrease in multimerization rate (Figure 1B). Minimal improve-
ment in the multimerization rate is obsered in a non-physiologic 0 mM potassium condition
(Figure S1), demonstrating that the protein is intact but defective in multimerization.
The sole known CASQ2 disease mutation with strong evidence for dominant inheritance,
K180R, was not reported to cause defects in multimerization and was proposed to act via
alternative mechanisms.[27]. The striking effect of S173I on CASQ2 mutimerization, combined
with the fact that other known CASQ2 point mutants exhibit the same biochemical defect,
prompted us to reexamine multimerization capacity of the K180R mutant. The turbidity assay
for K180R under the same conditions used for S173I shows little difference from the wild type
CASQ2 variant (Figure 1C). However, prior reports suggested that calsequestrin maintains
distinct magnesium and calcium binding sites.[28] Therefore, we investigated filamentation
kinetics of the K180R mutant in the presence of magnesium. Extended incubation of the
K180R mutant with magnesium (2 mM MgCl2) prior to addition of calcium yields a profound
filamentation defect (Figure 1D). In vivo, calsequestrin would likely encounter similar levels of
free magnesium throughout the SR.
As the dominant inheritance pattern is classically associated with disease mutations that
disrupt protein-protein interactions, we might expect to find dominant-acting disease mutations
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at cardiac calsequestrin’s dimer or multimer interfaces. However, neither S173 nor K180 fall
at credible, previously identified candidate multimerization interfaces: they are not near the
intra-dimer interface, nor are they near candidate inter-dimer interfaces in the prior crystal
structures. We therefore elected to pursue another structure in the belief that the biologically
relevant multimer has not yet been observed.
Overview of The New Candidate Structure of a Calsequestrin Filament
We have determined a new crystal structure of human cardiac calsequestrin obtained from
a full-length construct in a very low-pH (3-3.5) crystallization condition. The previously char-
acterized calsequestrin dimer is again observed, but now in an arrangement that produces a
closely-packed filament (Figure 2). The new structure provides a compelling candidate for a
biologically-plausible higher-order multimer. Crystallographic data collection and processing
statistics are summarized in (Table S1) for the native structure as well as a ytterbium-soaked
condition used to identify probable calcium-binding sites. The repeating unit of the native
crystal resides in a higher-symmetry point group compared to prior calsequestrin structures
(Table S2). The oligomer-forming contacts that exist between dimers are novel, differing sig-
nificantly from all previously reported calsequestrin crystal structures (Table S4). The inter-
dimer interface in our structure encompasses significantly greater buried surface area than
previously observed (Table S4).
The cardiac calsequestrin monomer, like its skeletal calsequestrin equivalent, consists of
an N terminal loop, 3 thioredoxin domains, and a disordered acidic tail. Within the dimer,
there is two-fold symmetry with mutual exchange of N-terminal loops, as previously observed
(Figure 3A). In our structure, the dimers are stacked along a screw axis to form the filament,
with each dimer rotated 90° with respect to its neighbors. Although the dimers are positioned
at discrete 90° rotations with respect to one another, the underlying architecture of the filament
is in fact helical at the level of thioredoxin domains (Figure 3A). Thioredoxin domains II and
III form a double helix at the core of the filament (Figure 3B). An outer helix or ”collar” of
larger diameter, consisting only of thioredoxin domain I, then winds around the inner double
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helix. All helices are left-handed, corresponding to the left-handed screw axis at the level of
dimer-stacking.
The 3-helix configuration appears to promote the close packing of globular thioredoxin
domains. Helical packing permits each domain to contact multiple other domains in multiple
other protomers, which is in stark contrast to other reported candidate structures (PDB ID
1A8Y, rabbit skeletal muscle calsequestrin; PDB ID 1SJI, canine cardiac calsequestrin), which
lack the helical pitch and have much more limited interacting surface area (Figure 4). The
close-packing of the new filament candidate is starkly visible when thioredoxin domains are
represented as equally-sized spheres centered at the domain center of mass (Figure 4, right-
hand side).
Notably, our crystallization condition produced crystals only at a low pH (3-3.5, measured
by applying a crystallization drop to litmus paper) resulting from the use of aged PEG reagents
(presumably having undergone degradation to glycolic acid) or from direct addition of concen-
trated HCl. This restriction obtained irrespective of calcium in concentrations ranging from
trace to 14 mM (higher calcium concentrations led to precipitation, likely due to the presence
of sulfate, and were therefore not assessed). Given calsequestrin’s remarkable overall acidity
and low isoelectric point, an explanation for the role of low pH in promoting calsequestrin fila-
mentation could be the neutralization of substantial negative charge on acidic side chains that
extend across the filament interfaces.
Lanthanide Substitution Identifies Cation-Binding Sites that Participate in Dimer
Formation
Prior work has identified putative calcium binding sites at the dimer interface of calsequestrin[25].
Our new filament structure permits us to examine the role of multivalent ions at all surfaces
relevant for filamentation - both the intra-dimer surfaces as well as the inter-dimer surfaces
responsible for higher-order multimers. To localize candidate calcium ligand sites within the
context of the new filament structure, we collected data from a Ytterbium (Yb)-soaked crys-
tal.(Table S1) From the anomalous map, we identified approximately 8 sites with strong Yb
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signal per CASQ2 chain (¿ 3.8 σ in the anomalous map and difference density in the Fo-Fc
map). As the prior work to identify calsequestrin’s calcium-binding sites was based largely
on the indirect method of inference from metal coordination geometry with nearby side chains
and waters, the use of Yb provides a direct approach to confirming the prior findings, as well
as extending our understanding to the entire filament.
We first assessed the presence of Yb at the intra-dimer interface. We identified several
high-occupancy Yb sites, most of which are clustered in a narrow region between protomers,
where they are coordinated by multiple, highly-conserved acidic residues (Figure 5 and Fig-
ure S2). Consistent with the location of a putative calcium ion in the prior study, we find
a Yb atom coordinated primarily by E147 of chain A and D278 of chain B. In addition, we
find a Yb atom coordinated primarily by E143 and E275, as well as another Yb atom coordi-
nated by D310 and a putative sulfate ion within a solvent cavity enclosed by the dimer. These
Yb-bridging sites stabilize the interaction between thioredoxin domain II from protomer A and
thioredoxin domain III of protomer B. The interactions between domains result in close juxtapo-
sition of acidic side chains (Figure 5), requiring neutralization of the charge by the multivalent
counterions or, in the case of the native structure, protonation. In the native structure, the
E147/D278 interaction provides an example of a carboxyl-carboxylate bond stabilized by low
pH.[29][28] Anomalous signal is found at this site in the derivative structure, but consistently
on just one side of the otherwise symmetric dimer. This subtle asymmetry, with a cation bound
on one side and a carboxyl-carboxylate bond on the other, likely reflects a degree difference
in occupancy rather than a sharp distinction, but it is a consistent feature of the density map
across all 4 dimers in the crystal asymmetric unit and may be conformationally conducive to
filament formation.
In both the native structure and Yb-soaked structure, the dimer subunits have undergone
substantial inward rotation in comparison to the other high-resolution cardiac calsequestrin
structure (PDB ID 1SJI) (Figure 5B). The inward domain movement is produced largely by
rotation of the monomer as a rigid body and results in a conformation where domains II and III
are more closely packed. This conformational shift recapitulates a similar finding from the prior
study where a 15° rotation within the skeletal calsequestrin dimer was observed for structures
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crystallized in a high-calcium buffer.[25] Upon inspection of all prior published calsequestrin
structures, it is apparent that 6 prior calsequestrin structures belong to this ”tightly-packed
dimer” group, while the remaining 10 contain dimers that are more loosely-packed, without in-
ward rotation of chains (Figure S3). The more tightly-packed structures were all crystallized in
the presence of multivalent cations (usually calcium), or in one case (PDB ID 2VAF) a mono-
valent cation at extremely high concentration ( 2 M NaCl. The other group were crystallized
with no added multivalent cations, with the exception of PDB ID 3TRP, which contained cal-
cium in the crystallization drop at approximately 5-fold lower than lowest concentration from
the tightly-packed group. Within the tightly-packed group, there is a greater degree of confor-
mational disorder in Domain I (Figure S4). This is accompanied by a modest loss of contact in
Domain I, while multiple hydrophobic side chains from Domains II and III that were not buried
now obtain buried surface area (Figure S5). Thus, our data provide additional evidence for
conformational change within the dimer upon calcium-binding (likely induced by closer ap-
proximation of acidic side chains), independent confirmation of intra-dimer calcium binding
sites, and an explanation for why an altered conformation of the dimer becomes energetically
tolerable in the presence of calcium.
Cation-Binding Promotes Filament Formation by Dimer-Dimer Stacking
Like the dimer interface, the inter-dimer filament-forming interface is bridged by Yb sites sur-
rounded by closely-apposed acidic side chains (Figure 6 and Figure S6). In contrast to the
dimer interface, where carboxyl-carboxylate bonds are still seen in the Yb-derivative structure,
at the inter-dimer interface the sites of carboyxl-carboylate interaction have been throughly
substituted with a cation. Identification of these coordination sites provides a testable model
for the biological correctness of the new filament structure. To test this model, we mutated
the aspartate or glutamate side chains involved in Yb binding to alanine and examined the
effect of the mutations on filamentation kinetics. The most pronounced effect resulted from
mutations targeting the symmetrical interaction involving E184 and E187 (Figure 6A). The Yb
site formed by these residues lies on the edge of a solvent cavity enclosed by the inter-dimer
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interface, partially shielded from exposure to the bulk solvent. Glutamates 184 and 187 be-
long to an alpha helix that provides a linkage between domains of the outer thioredoxin collar.
This helix, belonging to thioredoxin domain 2, sits between thioredoxin I domains of different
dimers and interacts with inter-dimer salt bridges on either side. Mutating E184 and E187
to alanine effectively prevents filamentation within the time period of observation.(Figure 6B).
Alanine mutagenesis of the D50 residue that participates in a salt bridge with K180 at the
N-terminal end of this helix produces a similar defect (Figure 6C).
Two more sites of strong Yb signal are notable. Residues D348 and D350 are oriented
along with their symmetry mates to form a cluster of 4 acidic side chains that coordinate a
single cation. As rendered in (Figure 6A), this Yb site forms the base of the solvent cavity en-
closed by the inter-dimer interface. Outside this cavity, on the fully solvent-exposed exterior of
the filament, residues D351 and E357 and their symmetry mates form bidentate interactions
with two Yb atoms, adopting conformations in which opposing acidic rotamers are bent away
from one another, thereby alleviating electrostatic repulsion that would otherwise disrupt mul-
timer formation (Figure 6A). In summary, the bound cation at these sites appears to facilitate
filamentation by neutralizing the abundant negative surface charge of calsequestrin. Mutating
these sites to alanine would be expected to relieve mutal repulsion of closely-packed acidic
side chains. Consistent with this, alanine mutagenesis of these residues has a largely net
neutral effect on filamentation kinetics (Figure S7).
Intriguingly, the vast majority of Yb sites that we identify are located within a continuous
solvent cavity that winds through the interior of the filament, forming a hollow core with solvent
exposure at the dimer and inter-dimer interfaces. Each dimer contains a solvent pocket within
its interior, with a second solvent cavity located at inter-dimer interface (Figure 7A-B). The
stacking of dimers forms a continuous solvent cavity along the entire length of the filament
(Figure 7). The calcium ions that would appear to be bound in the dimer’s interior would
constitute a separate store of calcium that is more slowly-mobilized than the highly-accessible
pool of ions bound to the surface and the solvated acidic tail.
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Dominant Disease Mutations Disrupt Cardiac Calsequestrin’s Inter-Dimer Inter-
face
The newly observed filament structure permits us to assess the possible pathogenic mecha-
nism of the S173I mutation that began this investigation. Remarkably, S173 occupies a critical
position at the filament-forming interface - a charged pocket formed by the interaction of K87,
S173, and D325 (Figure 8A and Figure S8. This pocket, formed of residues from 3 different
protomers and also 3 different thioredoxin domains, enforces an interaction between the 3
thioredoxin domains at a single site. This interaction explains the disruptive effect of the S173I
mutation discussed above (turbidity assay from Figure 1). On the basis of the apparent impor-
tance of this site, as well as the absence of D325 in any other previously described candidate
filament interface, we also mutated residue D325 to D325I. As expected, D325I exhibits similar
profound loss of function in the turbidity assay (Figure 8B).
The afore-mentioned K180 residue has recently been implicated in CPVT[27]. Specifi-
cally, a lysine-to-arginine mutation at this position provided the first strong genetic evidence
for a dominant CPVT-causing mutation in cardiac calsequestrin. Although this substitution is
relatively conservative, the genetic evidence for the pathogenicity of K180R as a dominant
mutation is compelling on the basis of a comprehensive segregation analysis in a large fam-
ily. As shown in Figure 1, the K180R mutation also results in a filamentation defect. Our
new structure provides a mechanistic explanation for this effect. In the new structure, K180
participates in helix-stapling salt bridges at the E184/E187 putative calcium site/interface re-
gion (Figure 6A) shown by us to be essential for robust filamentation.(Figure 6B) The high
conservation of K180 in evolution (Figure S9) and key role of K180 and its interacting part-
ners in supporting calsequestrin filamentation provide additional support for the physiological
relevance of our new structure.
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Discussion
We report here a crystal structure of a calsequestrin filament. We also elucidate the biochem-
ical basis of divalent cation-induced filamentation. Using Yb substitution, we confirm previ-
ous findings of intra-dimer cation binding sites, and we reveal additional inter-dimer cation
sites that have a substantial effect on the rate of multimerization. Furthermore, we provide
three forms of evidence in support of the biological relevance of the new structure: biophys-
ical (buried surface area, all-by-all interactions of protomers and domains), biochemical (dis-
ruption of multimerization by targeted mutagenesis), and biomedical (disease mutations with
dominant inheritance are located at the newly-identified filament-forming interfaces).
What is the proximal source of free energy for calsequestrin filamentation? The prevailing
view has been that calsequestrin filamentation is driven by an increase in solvent entropy:
ions are bound at filament interfaces, and solvent entropy increases as ion hydration shells are
lost.[28] Under this view, the net contribution from solvent entropy is much greater than the net
enthalpic contribution from calcium binding after considering the energetic cost of dehydration.
This hypothesis is complicated, however, by the fact that we observe stable filamentation in the
near-absence of ligand (only trace concentrations of divalent cations were present in the low-
pH crystallization condition). The low-pH filament is stabilized instead by carboxyl-carboxylate
interactions between closely juxtaposed acidic residues. While increased solvent entropy likely
contributes to filamentation, we postulate instead that protein conformational entropy is likely
to be the major driving force. The structure we report is remarkably disordered by conventional
B-factor metrics, and especially so in Domain I. In fact, all tightly-packed calsequestrin dimers
(7 crystallographic results total, including this study) exhibit increased disorder in the solvent-
exposed loops of Domain I (Figure S4). The consistency of this observation within the group
makes it less likely that conformational disorder within Domain I is a feature of our specific
crystallization condition and more likely that it is a result of the dimer having adopted the
tightly-packed conformation favorable for filamentation.
Although low pH may not be necessary for filamentation, calsequestrin’s pH-sensitivity
prompts questions about the possible role of intra-luminal pH changes in the regulation of cal-
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cium uptake and release. Carboxyl-carboxylate side chain interactions modulated by prevail-
ing pH are a common feature of calcium-binding proteins, wherein a shared proton provides
a stabilizing interaction when the cation is unavailable.[30][28] These carboxyl-carboxylate in-
teractions have a higher pKa than a solitary carboxylate, permitting them to play a significant
role at pH ranges closer to physiologic.[31][28] Even at neutral pH, studies of calsequestrin
and calmodulin have revealed that protons are released upon calcium binding, consistent with
loss of carboxyl-carboxylate bonds.[30][28] Notably, the SERCA pump, in addition to being an
ATPase, is a Ca2+/H+ antiporter, so it is reasonable to hypothesize that proton flows over the
course of a cycle of CICR have downstream regulatory effects on calsequestrin’s filamentation
state, or its affinity for calcium, or both. A small decrease in SR luminal pH during calcium
release has been observed[32], and multiple groups have proposed that proton influx into
the SR constitutes a small but important fraction of the counterion flow required to maintain
charge neutrality when large calcium fluxes occur. Proton efflux from the SR during calcium
reuptake, by way of the SERCA pump’s antiporter function, would increase the availability of
calcium binding sites. Conversely, protein influx into the SR during calcium release - possi-
bly via a second, independent proton transport pathway within the SERCA pump[33] - could
conceivably stabilize calsequestrin filaments until high levels of calcium are restored. Prior
work showed a change in calsequestrin’s intrinsic fluorescence at a pH of 6.0 [34], suggesting
that dynamic effects on calsequestrin are not limited to the low pH regime used in our crys-
tallization experiments. Since calsequestrin is present at high concentration and likely acts
non-trivially as a proton buffer in its own right, effects due to total free proton concentration
may manifest as protons move from an SR-based buffer system to one in the cytosol and back
with little change in detectable pH. It is important to note that presumed regulatory of effects
of dynamic SR pH are speculative and require further elucidation.
Strikingly, most known CASQ2 mutations that disrupt filamentation at the intra-dimer inter-
face (e.g. R33Q, D307H, and P308L) are associated with recessive inheritance, yet the mu-
tations investigated here (S173I, K180R) that disrupt filamentation at the inter-dimer interface
are associated with dominant inheritance. The apparent discrepancy in inheritance patterns,
mapping cleanly to distinct interfaces albeit with limited sampling, is notable. To date, the field
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has explained the recessive mechanism of intra-dimer interface mutations by way observing
that calsequestrins have no classical ER retention signal: filamentation is necessary for calse-
questrin to remain in the jSR.[13][14][15] In the setting of a heterozygously-carried mutation
that inhibits dimer formation, mutant monomers are eliminated by trafficking, such that the
pool of wild type protein would be largely unaffected. Under this model, filamentation defects
overlap mechanistically with a class of calsequestrin-deficient conditions arising from null or
hypomorphic alleles, all leading to a final common endpoint of decreased calcium-buffering
capacity, and a resulting susceptibility to diastolic calcium leak.
In seeming contrast to this model, poisoning of multimerization in classical dominant fash-
ion would require mutant-incorporating dimers to remain jSR-resident, where they could in-
terfere with assembly. There is no reason, however, based on current understanding of se-
cretory pathways, that the dimer would be any less susceptible than the monomer to export.
How, then, can the ER export mechanism be reconciled with dominant-acting filamentation-
defect mutants? If filamentation defects are equivalent at the molecular level to calsequestrin
deficiency, how do we explain the finding of filamentation-disrupting mutations with likely dom-
inant inheritance? We would propose that all filamentation-defective mutants within uninco-
porated dimers are trafficked out of the jSR in much the same way that unincoporated mutant
monomers are. The resulting disease mechanism for dominant mutations is therefore more
complex than a classical dominant negative effect: for as long as mutant-containing dimers
may be present in the jSR, they interfere with multimerization, but crucially, when they leave,
they steal half of the total WT protein with them. The result is paradoxical and perhaps some-
what novel: insufficiency by way of underlying dominant negative biochemistry.
In sum, taking into account calsequestrin’s demonstrated susceptibility to ER export, we
can combine the present work with the existing rich body of calsequestrin research to neatly
explain the inheritance puzzle associated with CPVT-causing calsequestrin mutations. Dimer-
defective mutants produce monomers which are trafficked away, but the heterozygous state
is rescued because WT protein is unaffected by the pool of defective monomeric protein. In
contrast, mutations that interfere with the inter-dimer interaction result in depletion of a sub-
stantial fraction of WT protein, as unincorporated dimers containing a mix of WT and mutant
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protein are continually lost. Future work should seek to confirm this hypothetical mechanism
using cell biological investigative methods.
Materials and Methods
Human Subjects
The patient included in the study provided informed consent as part of a research protocol
approved by the University of California, San Francisco Committee on Human Research.
Cloning and Generation of Plasmids
Full-length cardiac calsequestrin was cloned from human cardiac mRNA by reverse transcrip-
tion, PCR, A-tailing of a PCR product, and TA ligation. A clone lacking the signal peptide
sequence was subcloned by PCR and Gibson Assembly into a T7-based bacterial overex-
pression vector (pET28a) in front of a 6His site and TEV protease cleavage sequence. Site-
directed mutagenesis was performed to generate alanine mutants and CPVT mutants. All
constructs were transformed in NEB Stable or XL-1 Blue E. coli, purified by miniprep, and
retransformed into Rosetta (DE3)pLysS E. coli for overexpression. Selection for the pET28a
vector was performed using 50 µg/L kanamycin. Selection for pLysS was performed by adding
25 µg/L chlorampenicol.
Molecular Cloning
The human cardiac calsequestrin coding sequence was obtained by RT-PCR. Subsequent
cloning was performed by Gibson Assembly. The construct for protein expression was cloned
into a pET28a-based expression vector. This construct excluded the N-terminal signal peptide
but retained the remaining coding sequence, including the C-terminal acidic tail. Point mutants
were generated using the protocol from the Q5 Site-Directed Mutagenesis Kit (New England
BioLabs), using either the Q5 or Phusion polymerases. All constructs were verified by Sanger
sequencing. Primers used for cloning and mutagenesis are provided in Table S1.
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Expresssion and Purification of Cardiac Calsequestrin
pET28a-based expression constructs were miniprepped from a cloning strain and transformed
into Rosetta (DE3)pLysS E. coli. Overnight starter cultures were used to inoculate large cul-
tures (typically 750 mL of broth per 2.8 L flask), which were grown to OD 0.4 and then induced
with 0.25 mM IPTG. Upon induction, temperature was reduced from 37 ◦C to 24 ◦C. Cultures
were grown for 6-9 hours post-induction or overnight and then spun down (optimal yields were
obsered from shorter durations of growth). All cultures were grown in standard LB in 50 µg/L
kanamycin and 25 µg/L chlorampenicol. Pellets were resuspended in lysis buffer (20 mM Tris
pH 7.4, 500 mM NaCl, 10 mM imidazole, 1 EDTA-free protease inhibitor tablet per 50 mL) and
frozen at −80 ◦C. Frozen suspensions were thawed, sonicated on ice (5 min at 1 s on/1 s
off), and clarified (15,000 g, 45 min, 4 ◦C). The clarified supernatant was filtered (0.2 µm), and
calsequestrin-containing fractions were isolated by IMAC using a 5 mL HisTrap FF column
attached to a GE Akta FPLC (IMAC Buffer A: 20 mM Tris pH 7.4, 500 mM NaCl, 10 mM imida-
zole; IMAC Buffer B: 20 mM Tris pH 7.4, 500 mM NaCl, 300 mM imidazole). Protein was eluted
in 10% steps of Buffer B. The first eluted fraction (10% Buffer B) was always discarded (con-
sistently observed to be impure as determined by SDS-PAGE). Remaining protein-containing
fractions were pooled. TEV protease was added to the pooled fractions at a concentration of
1:40 by mass, and the protein was dialyzed overnight at 4 ◦C in TEV protease dialysis buffer
(50 mM Tris pH 8.0, 0.5 mM EDTA, 1 mM DTT). The cleaved protein was further dialyzed for
several hours in EDTA dialysis buffer (20 mM HEPES pH 7.3, 100 mM NaCl, 5 mM EDTA) and
then overnight into Anion Exchange Buffer A (20 mM HEPES pH 7.3, 100 mM NaCl). Anion
exchange polishing was performed using a HisTrap FF column in series with 3x1 mL Mono Q
columns. (Buffer A: 20 mM HEPES pH 7.3, 100 mM NaCl; Buffer B: 20 mM HEPES pH 7.3, 1
M NaCl). Protein was eluted in a continuous gradient up to 100% Buffer B), with calsequestrin-
rich fractions consistently eluting at 40-50% Buffer B. Fractions were collected and analyzed
for purity by SDS-PAGE and A260/A280 ratio. Fractions that were optimally pure and free of
A260 contamination were pooled, concentrated to 20 mg/mL, and frozen at −80 ◦C.
Alanine mutants and the D325I mutant were purified as described above, except that phos-
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phate IMAC buffers were employed (Buffer A: phosphate buffer at pH 7.4, 500 mM NaCl, 10
mM imidazole; Buffer B: phosphate buffer at pH 7.4, 500 mM NaCl, 300 mM imidazole), and an
on-column high-salt wash was performed (phosphate buffer at pH 7.4, 2 M NaCl). In addition,
the TEV protease dialysis buffer used for these purifications contained 100 mM NaCl.
Crystallization of Cardiac Calsequestrin (Native Conditions)
Crystallization screens were carried out in 96-well hanging-drop format and monitored using a
Formulatrix Rock Imager automated imaging system. Conditions conducive to crystal growth
were optimized and then reproduced in a 24-well format. The best diffraction was obtained
by mixing thawed protein (10–20 mg mL−1 in 20 mM HEPES pH 7.3, 400–500 mM NaCl) 1:1
with 15% PEG 4000 and 400 mM Li2SO4. The pH of the PEG 4000 solution used to produce
the best-diffracting crystals was tested by litmus paper and found to be approximately 3-3.5.
Despite the presence of 20 mM HEPES in the protein reagent, the pH of the drops in which
cystals grew was controlled by the PEG and remained 3-3.5. Freshly-made PEGs were
incompatible with calsequestrin crystal growth except when concentrated HCl was added to
the mother liquor, producing crystals similar to those observed with benchtop-aged PEGs.
Interestingly, only unbuffered conditions yielded crystals. Multiple attempts to grow crystals at
a buffered low pH (using acetate or glycine-based buffers) failed.
Ytterbium Soak
We initially attempted to identify calcium sites using anomalous signal from calcium (CaCl2)
added to the crystallization condition described above. We were unsuccessful, likely due to a
combination of several factors. The calcium absorption edge is unreachable with conventional
tunable x-ray sources and in normal atmosphere; thus it can only be approached, with result-
ing weakened anomalous signal. In addition, calsequestrin has an average K d for calcium of
1 mM. Thus occupancy at a typical site would be expected to be lower as compared to other
calcium-binding proteins. Presence of sulfate in the crystallization condition limited calcium
concentrations to approximately 14 mM and below, above which a precipitate was observed.
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Although this limit is above the K d, it was insufficient for robust anomalous signal. Crystals
of calsequestrin that formed in trace calcium were therefore soaked in YbCl3. Hanging drops
containing calsequestrin crystals were uncovered and an Eppendorf Microloader was used to
inject 2 µL drops (1 µL protein and 1 µL mother liquor) with 200 µL of 2 M YbCl3. Data were
collected within 5 minutes with no back-soaking.
Crystal Data Collection and Structure Determination
Hanging drops were uncovered and submerged in a drop of Parabar 10312 (previously known
as Paratone). For Yb-soaks, Yb was quickly injected prior to application of the oil. Crys-
tals were looped and pulled through the oil. Excess oil was blotted away, and the loop was
mounted directly into the cryostream of the Tom-Alber-Tron endstation at ALS beamline 8.3.1.
Frames were collected at 1.116 keV (1.386 keV for Yb-soaked crystals) using the endstation’s
Pilatus3 S 6M detector using a strategy designed to balance redunancy against radiation
damage.
Structure Determination
Diffraction images were processed with xia2 using the DIALS integration pipeline using a res-
olution cutoff of CC1/2 ¿ 0.3.[35][36][37][38][39] For the native structure, the merged diffraction
intensities were used to find a molecular replacement solution in Phaser[40] with the previ-
ously published canine cardiac calsequestrin structure, 1SJI[11], serving as the initial model.
This resulted in solution in space group P4322 containing one calsequestrin chain per AU. This
solution was refined in PHENIX[41] with PHENIX AutoBuild[41][42][43][44][45], with extensive
manual model-building in Coot[46]. For the Yb-complexed dataset, data were processed as
above but with preservation of anomalous signal (no merging of Friedel pairs). The refined
native structure was used a molecular replacement model, and a solution was found in space
group P43212 containing a dimer in the AU. This solution refined poorly. The Yb-complexed
dataset was reprocessed in P1, and a molecular replacement solution was found in P1 with 16
chains in the AU. Refinement of this model was tested using Zanuda[47], and the best R-free
17
was found to be in space group P1211. The Yb-complexed dataset was reprocessed in space
group P1211, and a molecular replacement solution was found with 8 chains in the AU. This
solution refined well. The anomalous map was used in refinement to place Yb atoms in the
structure.
Turbidity Assays
Recombinant protein samples were thawed, diluted in 2 mL–3 mL of Turbidity Assay Buffer
(15 mM Tris pH 7.4, 20 mM NaCl, 85 mM KCl) and dialyzed in Turbidity Assay Buffer plus
10 mM EDTA. Samples were then redialyzed overnight in the same buffer without EDTA. Ap-
proximately half of the sample was then dialyzed in Zero-Potassium Turbidity Assay Buffer
(15 mM Tris pH 7.4, 20 mM NaCl). Protein A280 was measured in triplicate (Nanodrop) using
the appropriate matching buffer as background, and protein was diluted to 2.25 µM in a 140 µL
volume in half-area wells of a µClear 96-well plate. The plate was covered, and protein in
the wells was allowed to equilibrate on the benchtop for 20 minutes. The turbidity assay was
performed using a BioTek Synergy 2 plate reader equipped with reagent injectors. Seven µL
of 20 mM CaCl2 solution was injected into each well, and the plate underwent shaking for 20 s.
Absorbance at 350 nm was monitored for 45 min. The protocol was performed in plate syn-
chronized mode for consistent well-to-well timing. A 100 mM ion-selective electrode calcium
standard (Sigma, cat no. ) stock solution was used for all CaCl2 dilutions.
Quantification and Statistical Methods
Data points in figures represent mean values, with error bars representing standard deviation.
All turbidity assay data points are mean of 3 technical replicates.
Data and Software Availability
The structures determined as part of this work are deposited in the Protein Data Bank (PDB)
under identifiers 6OWV (native) and 6OWW (ytterbium-soaked). The raw diffraction dataset
for the native structure is deposited in Zenodo under doi:10.5281/zenodo.2941360. The raw
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diffraction dataset for the ytterbium-soaked structure is likewise deposited in Zenodo under
doi:10.5281/zenodo.2943248. Protein structure figures were generated using PyMOL.[48]
The interior cavity of the calsequestrin filament was traced using HOLLOW.[49] Sequence
alignments were generated using TEXshade.[50] Plots were generated using python matplotlib.[51]
The manuscript and figure layouts were constructed entirely in LATEX using PGF/TikZ. Data
and code to generate all figures are freely available at https://github.com/errontitus/
casq2-structure-function.
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Figure 1: Dominant-acting CASQ2 disease mutations disrupt calsequestrin multimerization.
(A) Pedigree of a large extended family with the S173I mutation and a CPVT-like phenotype. CABG = coronary
artery bypass graft; CAD = coronary artery disease; CHD = congenital heart disease; ETT = exercise treadmill
test; MI = myocardial infarction; SCD = suddent cardiac death; SIDS = sudden infant death syndrome.
(B) Multimerization kinetics of the S173I mutant observed using a turbidity assay after addition of 1 mM CaCl2 to
purified protein (pH 7.4, 20 mM NaCl, 85 mM KCl).
(C) Multimerization kinetics of the K180R mutant observed using a turbidity assay (same conditions as in B).
(D) Multimerization kinetics of the K180R mutant observed using a turbidity assay (same conditions as in B, but
with 2 mM MgCl2 added prior to calcium).
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Figure 2
Cardiac Calsequestrin Filament Dimer
Chain A Chain B
Chain A’
Chain B’
Figure 2: The cardiac calsequestrin filament candidate structure is assembled from calsequestrin dimers assem-
bled on a screw axis with 90 degrees of rotation per dimer. The cardiac calsequestrin candidate filament (PDB ID
6OWV) is shown, along with a representative dimeric and tetrameric assembly.
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Figure 3
A
Cardiac Calsequestrin Filament (Colored by Thioredoxin Domain)
Three Thioredoxin Domains per Chain
B
Thioredoxin Domain II/III Double Helix
Figure 3: Viewed at the level of its thioredoxin domains (3 per protomer), the cardiac calsequestrin filament
consists of an inner thioredoxin double helix with an outer thioredoxin single helix wrapping the double helical
core.
(A) The cardiac calsequestrin filament rendered with thioredoxin domain colors, revealing the helical character
of the filament. The outer single helix, consisting of domain I, winds around an inner double helix consisting of
domains II and III. Cardiac calsequestrin monomers are colored by thioredoxin domain (domain I, purple; domain I,
cyan; domain III, yellow). The monomers are translated but remain in their dimer-forming orientation with two-fold
symmetry.
(B) The inner double helix of the cardiac calsequestrin filament consisting of thioredoxin domains II and III.
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Figure 4
6OWV, 2019, human cardiac calsequestrin
A
1A8Y, 1998, Rabbit skeletal calsequestrin
B
1SJI, 2005, Canine cardiac calsequestrin
C
Figure 4: Prior putative calsequestrin filament candidates have fewer inter-domain contacts, fewer inter-protomer
contacts, and substantially less buried surface area compared to the new candidate. The new candidate CASQ2
filament exhibits tight packing of protomers and thioredoxin domains (shown on the right using equal-size spheres
placed at the center of mass of each thioredoxin domain).
(A) The new candidate cardiac calsequestrin filament assembled from crystallographic symmetry operations on
6OWV (human CASQ2, 2019).
(B) A putative skeletal calsequestrin filament assembled from crystallographic symmetry operations on 1A8Y (rab-
bit CASQ1, 1998).
(C) A putative skeletal calsequestrin filament assembled from crystallographic symmetry operations on 1SJI (ca-
nine CASQ2, 2005).
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Figure 5
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Figure 5: The intra-dimer interface of cardiac calsequestrin contains likely sites of calcium binding (identified by
ytterbium anomalous signal).
(A) Dimer with Yb sites (magenta spheres) within its interior cavity. Closeups focus on Yb positions that bridge
dimer chains A and B.
(B) Comparison of a previously published cardiac calsequestrin dimer (1SJI) to the more tightly-packed dimer that
we report. The tightly-packed dimer results primarily from rigid body rotation of the dimer chains inward (for a
single chain, we observe 20° counter-clockwise rotation in the plane of the page when the other chain is fixed
to the reference dimer). The inward rotation produces an increase in buried surface area (BSA) in thioredoxin
domains II and III.
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Figure 6: The inter-dimer interface of cardiac calsequestrin contains likely sites of calcium binding (identified by
ytterbium anomalous signal). Disruption of these sites leads to filamentation defect.
(A) Yb (magenta spheres) bound within the walled pocket formed by the inter-dimer interface, with closeups of
ytterbium site at E184 and E187, D348 and D350, and D351 and D357. Thioredoxin domain II of chain A’ (blue) is
omitted to allow visualization of the interior of the solvent pocket formed by the inter-dimer interface.
(B) Turbidity assay after alanine mutagenesis of the D50 residue that participates in a salt bridge with K180,
adjacent to the E184/E187 ligand site.
(C) Turbidity assay after alanine mutagenesis of putative calcium-binding residues E184 and E187.
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Figure 7
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Figure 7: The cardiac calsequestrin filament possesses a continuous solvent-accessible interior cavity that winds
along the filament long axis.
(A) The interior cavity of the dimer (colored cyan) as traced by HOLLOW using a 1.4 A˚probe. Also shown is the
interior cavity viewed down its long axis. Residues that participate in the coordination of Yb atoms within the intra-
dimer cleft (Figure 5) are shown as sticks. All other residues are rendered as surface.
(B) The lumen of the dimer is continuous with a large solvent pocket formed by the tetramer interface.
(C) View of the filament and its continuous interior cavity, with Yb sites shown as purple spheres.
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Figure 8
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Figure 8: The cardiac calsequestrin S173 residue is located at a highly hydrophilic 3-protomer interface within the
inter-dimer contact region. Disruption of this hydrophilic pocket by hydrophobic substitution leads to filamentation
defect.
(A) Inter-dimer interface with with interface residues in the S173 region rendered as spheres. the closeup panel
shows a charged pocket at the inter-dimer interface where the CPVT-associated S173I mutation is found. In this
pocket, 3 different thioredoxin domains from 3 distinct chains interact (K87, S173, D325).
(B) Turbidity assay with the D325I mutation.
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Supplemental Figures
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Figure S1: Multimerization kinetics of the S173I mutant observed in 0 mM KCl.
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Figure S2
A
Native map at 1.5 σ Yb-complexed map at 1.5 σ Yb-complexed anomalous map at 3.0 σ
B
Native map at 1.5 σ Yb-complexed map at 1.5 σ Yb-complexed anomalous map at 3.0 σ
Figure S2: Electron density maps for Yb-binding sites at the cardiac calsequestrin intra-dimer interface.
(A) Electron density maps for the D140/E143/E147 region of interest.
(B) Electron density maps for the D310 region of interest.
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Figure S3
A
2VAF 3UOM 5CRG 5CRH
5KN1 5KN2
Overlays of tightly-packed dimers from published calsequestrin structures
onto the tightly-packed cardiac calsequestrin dimer from this study (6OVW)
B
1A8Y 1SJI 3TRP 3TRQ
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5KN0 5KN3
Overlays of loosely-packed dimers from published calsequestrin structures
onto the tightly-packed cardiac calsequestrin dimer from this study (6OVW)
Figure S3: Overlays of dimers from published calsequestrin structures (ligher orange and green) onto the tightly-
packed dimer from this study (darker orange and green) reveals two distinct conformational groupings. The more
tightly-packed conformation with inwardly-rotated chains is correlated with presence of neutralizing cations. Dimers
are aligned on one chain (chain A arbitrarily chosen) to show degree of inward rotation in the other chain.
(A) Overlays of tightly-packed dimer structures.
(B) Overlays of loosely-packed dimer structures.
31
Figure S4
A
6OVW (This Study) 2VAF 3UOM 5CRG 5CRH
5KN1 5KN2
B-factor spectrum of tightly-packed dimers in published calsequestrin structures
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B-factor spectrum of loosely-packed dimers in published calsequestrin structures
Figure S4: Comparing B-factors between tightly-packed and loosely-packed calsequestrin dimers reveals that the
tightly-packed dimer exhibits increased conformational disorder in domain I.
(A) B-factor spectrum of tightly-packed dimers in published calsequestrin structures, with region of increased
disorder boxed. In PDB 6OVW, corresponding to this study, the disordered loop region is omitted entirely due to
the high level of disorder.
(B) B-factor spectrum of loosely-packed dimers in published calsequestrin structures.
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Figure S5
25. 30. 35. 40. 45. 50. 55. 60. 65. 70. 75. 80. 85.
PDB.6OWV.Homo.CASQ2 GLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEH 86
PDB.2VAF.Homo.CASQ2 GLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEH 86
PDB.3UOM.Homo.CASQ1 GLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLED 86
PDB.5KN1.Bos.CASQ1 GLDFPEYDGVDRVVNVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMDELILELAAQVLED 86
PDB.5KN2.Bos.CASQ1 GLDFPEYDGVDRVVNVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMDELILELAAQVLED 86
PDB.1A8Y.Oryct.CASQ1 GLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLED 86
PDB.1SJI.Canis.CASQ2 GLNFPTYDGKDRVVSLSEKNFKQVLKKYDLLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEH 86
PDB.3TRP.Oryct.CASQ1 GLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLED 86
PDB.3TRQ.Oryct.CASQ1 GLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLED 86
PDB.3US3.Oryct.CASQ1 GLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLED 86
PDB.3V1W.Oryct.CASQ1 GLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLED 86
PDB.5CRD.Homo.CASQ1 GLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLED 86
PDB.5KN0.Bos.CASQ1 GLDFPEYDGVDRVVNVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMDELILELAAQVLED 86
PDB.5KN3.Bos.CASQ1 GLDFPEYDGVDRVVNVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMDELILELAAQVLED 86
90. 95. 100. 105. 110. 115. 120. 125. 130. 135. 140. 145. 150.
PDB.6OWV.Homo.CASQ2 KAIGFVMVDAKKEAKLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISS 151
PDB.2VAF.Homo.CASQ2 KAIGFVMVDAKKEAKLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISS 151
PDB.3UOM.Homo.CASQ1 KGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLEDPVELIEG 151
PDB.5KN1.Bos.CASQ1 KGVGFGMVDSEKDAAVAKKLGLTEEDSVYVFKGDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
PDB.5KN2.Bos.CASQ1 KGVGFGMVDSEKDAAVAKKLGLTEEDSVYVFKGDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
PDB.1A8Y.Oryct.CASQ1 KGVGFGLVDSEKDAAVAKKLGLTEEDSIYVFKEDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
PDB.1SJI.Canis.CASQ2 KAIGFVMVDAKKEAKLAKKLGFDEEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISS 151
PDB.3TRP.Oryct.CASQ1 KGVGFGLVDSEKDAAVAKKLGLTEEDSIYVFKEDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
PDB.3TRQ.Oryct.CASQ1 KGVGFGLVDSEKDAAVAKKLGLTEEDSIYVFKEDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
PDB.3US3.Oryct.CASQ1 KGVGFGLVDSEKDAAVAKKLGLTEEDSIYVFKEDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
PDB.3V1W.Oryct.CASQ1 KGVGFGLVDSEKDAAVAKKLGLTEEDSIYVFKEDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
PDB.5CRD.Homo.CASQ1 KGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLEDPVELIEG 151
PDB.5KN0.Bos.CASQ1 KGVGFGMVDSEKDAAVAKKLGLTEEDSVYVFKGDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
PDB.5KN3.Bos.CASQ1 KGVGFGMVDSEKDAAVAKKLGLTEEDSVYVFKGDEVIEYDGEFSADTLVEFLLDVLEDPVELIEG 151
155. 160. 165. 170. 175. 180. 185. 190. 195. 200. 205. 210. 215.
PDB.6OWV.Homo.CASQ2 KLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDF 216
PDB.2VAF.Homo.CASQ2 KLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDF 216
PDB.3UOM.Homo.CASQ1 ERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.5KN1.Bos.CASQ1 ERELQAFENIEDDNKLIGYFKNKDSEHYKAYEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.5KN2.Bos.CASQ1 ERELQAFENIEDDNKLIGYFKNKDSEHYKAYEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.1A8Y.Oryct.CASQ1 ERELQAFENIEDEIKLIGYFKNKDSEHYKAYEEAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.1SJI.Canis.CASQ2 KLEVQAFERIEDYIKLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLKMNEVDF 216
PDB.3TRP.Oryct.CASQ1 ERELQAFENIEDEIKLIGYFKNKDSEHYKAYEEAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.3TRQ.Oryct.CASQ1 ERELQAFENIEDEIKLIGYFKNKDSEHYKAYEEAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.3US3.Oryct.CASQ1 ERELQAFENIEDEIKLIGYFKNKDSEHYKAYEEAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.3V1W.Oryct.CASQ1 ERELQAFENIEDEIKLIGYFKNKDSEHYKAYEEAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.5CRD.Homo.CASQ1 ERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.5KN0.Bos.CASQ1 ERELQAFENIEDDNKLIGYFKNKDSEHYKAYEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
PDB.5KN3.Bos.CASQ1 ERELQAFENIEDDNKLIGYFKNKDSEHYKAYEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDF 216
220. 225. 230. 235. 240. 245. 250. 255. 260. 265. 270. 275. 280.
PDB.6OWV.Homo.CASQ2 YEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDDLNGIHIVAFAEKSDPDG 281
PDB.2VAF.Homo.CASQ2 YEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDDLNGIHIVAFAEKSDPDG 281
PDB.3UOM.Homo.CASQ1 YEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDG 281
PDB.5KN1.Bos.CASQ1 YEAFMEEPVTIPDKPNSEEEIVSFVEAHKRSTLRKLKPESMYETWEDDLDGIHIVAFAEETDPDG 281
PDB.5KN2.Bos.CASQ1 YEAFMEEPVTIPDKPNSEEEIVSFVEAHKRSTLRKLKPESMYETWEDDLDGIHIVAFAEETDPDG 281
PDB.1A8Y.Oryct.CASQ1 YEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDG 281
PDB.1SJI.Canis.CASQ2 YEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDDLNGIHIVAFAEKSDPDG 281
PDB.3TRP.Oryct.CASQ1 YEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDG 281
PDB.3TRQ.Oryct.CASQ1 YEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDG 281
PDB.3US3.Oryct.CASQ1 YEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDG 281
PDB.3V1W.Oryct.CASQ1 YEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDG 281
PDB.5CRD.Homo.CASQ1 YEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDG 281
PDB.5KN0.Bos.CASQ1 YEAFMEEPVTIPDKPNSEEEIVSFVEAHKRSTLRKLKPESMYETWEDDLDGIHIVAFAEETDPDG 281
PDB.5KN3.Bos.CASQ1 YEAFMEEPVTIPDKPNSEEEIVSFVEAHKRSTLRKLKPESMYETWEDDLDGIHIVAFAEETDPDG 281
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285. 290. 295. 300. 305. 310. 315. 320. 325. 330. 335. 340. 345.
PDB.6OWV.Homo.CASQ2 YEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEI 346
PDB.2VAF.Homo.CASQ2 YEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEI 346
PDB.3UOM.Homo.CASQ1 FEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEM 346
PDB.5KN1.Bos.CASQ1 YEFLETLKAVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFNIDLSAPQIGVVNVTDADSVWMEM 346
PDB.5KN2.Bos.CASQ1 YEFLETLKAVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFNIDLSAPQIGVVNVTDADSVWMEM 346
PDB.1A8Y.Oryct.CASQ1 YEFLEILKSVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEM 346
PDB.1SJI.Canis.CASQ2 YEFLEILKQVARDNTDNPDLSILWIDPDDFPLLVAYWEKTFKIDLFRPQIGVVNVTDADSVWMEI 346
PDB.3TRP.Oryct.CASQ1 YEFLEILKSVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEM 346
PDB.3TRQ.Oryct.CASQ1 YEFLEILKSVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEM 346
PDB.3US3.Oryct.CASQ1 YEFLEILKSVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEM 346
PDB.3V1W.Oryct.CASQ1 YEFLEILKSVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEM 346
PDB.5CRD.Homo.CASQ1 FEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEM 346
PDB.5KN0.Bos.CASQ1 YEFLETLKAVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFNIDLSAPQIGVVNVTDADSVWMEM 346
PDB.5KN3.Bos.CASQ1 YEFLETLKAVAQDNTDNPDLSIIWIDPDDFPLLVPYWEKTFNIDLSAPQIGVVNVTDADSVWMEM 346
350.
PDB.6OWV.Homo.CASQ2 PDDDD 351
PDB.2VAF.Homo.CASQ2 PDDDD 351
PDB.3UOM.Homo.CASQ1 DDEED 351
PDB.5KN1.Bos.CASQ1 DDEED 351
PDB.5KN2.Bos.CASQ1 DDEED 351
PDB.1A8Y.Oryct.CASQ1 DDEED 351
PDB.1SJI.Canis.CASQ2 PDDDD 351
PDB.3TRP.Oryct.CASQ1 DDEED 351
PDB.3TRQ.Oryct.CASQ1 DDEED 351
PDB.3US3.Oryct.CASQ1 DDEED 351
PDB.3V1W.Oryct.CASQ1 DDEED 351
PDB.5CRD.Homo.CASQ1 DDEED 351
PDB.5KN0.Bos.CASQ1 DDEED 351
PDB.5KN3.Bos.CASQ1 DDEED 351
X acidic (−)
X basic (+)
X polar uncharged
X hydrophobic nonpolar
Figure S5: Multiple sequence alignment from published calsequestrin structures, grouped by dimer conformational
class (top group: compact dimer; bottom group: relaxed dimer). Intra-dimer interface residues are highlighted;
color represents hydropathy. Rotation of chains in compacted dimers leads to loss of contacts near the N terminus
but gain of contacts elsewhere. Calsquestrin structures 5CRE, 5CRG, and 5CRH are omitted (point mutants
belonging to the same investigation as 5CRD).
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Figure S6
A
Native map at 1.5 σ Yb-complexed map at 1.5 σ Yb-complexed anomalous map at 5.0 σ
B
Native map at 1.5 σ Yb-complexed map at 1.5 σ Yb-complexed anomalous map at 3.0 σ
C
Native map at 1.5 σ Yb-complexed map at 1.5 σ Yb-complexed anomalous map at 3.0 σ
Figure S6: Electron density maps for Yb-binding sites at the cardiac calsequestrin inter-dimer interface.
(A) Electron density maps for the D50/K180/E184/E187 region of interest.
(B) Electron density maps for the D348/D350 region of interest.
(C) Electron density maps for the D351/E357 region of interest.
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Figure S7: Turbidity assays showing effect of alanine mutagenesis of additional Yb-binding sites at the cardiac
calsequestrin inter-dimer interface.
(A) Turbidity assay after alanine mutagenesis of the putative calcium-coordinating residues D348 and D350.
(B) Turbidity assay after alanine mutagenesis of the putative calcium-coordinating residues D351 and E357.
Figure S8
Native map at 1.5 σ
Figure S8: Electron density map for the S173 region at the cardiac calsequestrin inter-dimer interface.
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Figure S9
CASQ2_Homo_sapiens MKRTHLFIVGIYFL.....SSCRAEEGLNFPTYDGKDRVVSLSEKNFKQVLKKYD 50
CASQ2_Canis_lupus_familiaris MKRTHLFIAGLYLL.....ASCRAEEGLNFPTYDGKDRVVSLTEKNFKQVLKKYD 146
CASQ2_Mus_musculus MKRIYLLMVGVYLL.....SLSGAEEGLNFPTYDGKDRVVSLSEKNLKQMLKRYD 50
CASQ2_Gallus_gallus MKATCWILAGFCLL.....FCCKAEEGLNFPTYDGKDRVIDLNEKNYKHALKKYD 50
CASQ2_Pelodiscus_sinensis ..MICWLLAGFYLF.....FCCRAEEGLDFPAYDGKERVFDLNEKNYKQALKKYD 48
CASQ1_H_sapiens GLRLALLLLLVLGTP...KSGVQGQEGLDFPEYDGVDRVINVNAKNYKNVFKKYE 65
CASQ1_C_lupus_familiaris GLPLALLLLLVLGPP...RLGVQGEEGLEFPEYDGVDRVVNVNAKNYKNVFKKYE 65
CASQ1_M_musculus ELRLALLFVLVLGTP...RLGVQGEDGLDFPEYDGVDRVINVNAKNYKNVFKKYE 65
CASQ1_X_tropicalis LLLLCLLIALCLALA...NLGARAEEGLDFPEYDGEDRVININLKNYKAALKKYE 68
CASQ1_C_elegans LASLALVVVLASAGISKNEDLECMFLGYPDLEYDGFDRTEVLTEKNFNRTVFAED 60
CASQ2_Homo_sapiens LLCLYYHEPVSSDKVTQKQFQLKEIVLELVAQVLEHKAIGFVMVDAKKEAKLAKK 105
CASQ2_Canis_lupus_familiaris VLCLYYHESVSSDKVAQKQFQLKEIVLELVAQVLEHKDIGFVMVDAKKEAKLAKK 201
CASQ2_Mus_musculus LLCLYYHEPVSSDKVSQKQFQLKEIVLELVAQVLEHKNIGFVMVDSRKEAKLAKR 105
CASQ2_Gallus_gallus MLCLLFHEPVSSDRVSQKQFQMTEMVLELAAQVLEPRSIGFGMVDSKKDAKLAKK 105
CASQ2_Pelodiscus_sinensis MLCLLFHEPVGSDKVSQKQFQMTEMVLELAAQVLEPKGIGFGFVDSKKDAKLAKK 103
CASQ1_H_sapiens VLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKK 120
CASQ1_C_lupus_familiaris VLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKK 120
CASQ1_M_musculus VLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKK 120
CASQ1_X_tropicalis VLALLYHEPIEDDKASQRQFEMEELIFELAAQVLEDKGVGFGLVDSEKDAAVAKK 123
CASQ1_C_elegans TKSVVFFNDVEEDDSELDQY...ECFLQLSAQIMTKRGYNFYTVNTTKEHRLRKQ 112
CASQ2_Homo_sapiens LGFD.EEGSLYILKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIISSKLEVQAFE 159
CASQ2_Canis_lupus_familiaris LGFD.EEGSLYVLKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIINSKLEVQAFE 255
CASQ2_Mus_musculus LGFS.EEGSLYVLKGDRTIEFDGEFAADVLVEFLLDLIEDPVEIVNNKLEVQAFE 159
CASQ2_Gallus_gallus LGLV.EEGSLYVFKEERLIEFDGELATDVLVEFLLDLLEDPVEIINSKLELQAFD 159
CASQ2_Pelodiscus_sinensis LGLD.EEGSLYIFKEERMIEFDGELAADVLVEFLLDLLEDPVELINSKLELQAFD 157
CASQ1_H_sapiens LGLT.EVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLEDPVELIEGERELQAFE 174
CASQ1_C_lupus_familiaris LGLT.EEDSIYVFKGDEVIEYDGEFSADTLVEFLLDVLEDPVELIEGERELQAFE 174
CASQ1_M_musculus LGLT.EEDSVYVFKGDEVIEYDGEFSADTLVEFLLDVLEDPVELIEGERELQAFE 174
CASQ1_X_tropicalis LGLD.EEDSIYVFKDDEVIEYDGEFSADTLVEFLLDVLEDPVEFIEGSHELAAFE 177
CASQ1_C_elegans EEVEKGEDTIHVYKDGYKIEYNGVRDPETFVSWLMDIPDDPVTIINDEHDLEEFE 167
CASQ2_Homo_sapiens RIEDYI.KLIGFFKSEDSEYYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLK.MN 212
CASQ2_Canis_lupus_familiaris RIEDQI.KLIGFFKSEESEYYKAFEEAAEHFQPYIKFFATFDKGVAKKLSLK.MN 308
CASQ2_Mus_musculus RIEDQT.KLLGFFKNEDSEYYKAFQEAAEHFQPYIKFFATFDKAVAKKLSLK.MN 212
CASQ2_Gallus_gallus QIDDEI.KLIGYFKGEDSEHYKAFEEAAEHFQPYVKFFATFDKGVAKKLGLK.MN 212
CASQ2_Pelodiscus_sinensis RIEDEI.KLIGYFKGEDSEHYKAFEEAAEHFQPYIKFFATFDKGVAKKLALK.LN 210
CASQ1_H_sapiens NIEDEI.KLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLK.LN 227
CASQ1_C_lupus_familiaris NIEDEI.KLIGYFKNKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLK.LN 227
CASQ1_M_musculus NIEDEI.KLIGYFKSKDSEHYKAYEDAAEEFHPYIPFFATFDSKVAKKLTLK.LN 227
CASQ1_X_tropicalis NIEEDQ.KLIGYFKNEDSEHYKAFVDAAEEFHPYIPFFATFDSKVAKKLDLK.IN 230
CASQ1_C_elegans NMDDECVRIIGYFEP.GSVALKEFEEAAEDFMGEIEFFAVVTSKWARKVGLKRVG 221
CASQ2_Homo_sapiens EVDFYEPFMDEPIAIPNKPYTEEELVEFVKEHQRPTLRRLRPEEMFETWEDDLNG 267
CASQ2_Canis_lupus_familiaris EVDFYEPFMDEPIAIPDKPYTEEELVEFVKEHQRPTLRRLRPEDMFETWEDDLNG 363
CASQ2_Mus_musculus EVGFYEPFMDEPNVIPNKPYTEEELVEFVKEHQRPTLRRLRPEDMFETWEDDLNG 267
CASQ2_Gallus_gallus EVDFYEPFMDEPVHIPDKPYTEEELVEFVKEHKRATLRKLRPEDMFETWEDDMEG 267
CASQ2_Pelodiscus_sinensis EVDFYEPFMDEPVHIPDKPYTEGELVEFVKEHRRATLRKLRPEDMFETWEDDLDG 265
CASQ1_H_sapiens EIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDG 282
CASQ1_C_lupus_familiaris EIDFYEAFMEEPVTIPDKPNSEEEIVSFVEEHRRSTLRKLKPESMYETWEDDMDG 282
CASQ1_M_musculus EIDFYEAFMEEPMTIPDKPNSEEEIVSFVEEHRRSTLRKLKPESMYETWEDDLDG 282
CASQ1_X_tropicalis EIDYYEPFHDEPVTIPNKPNSEEEIVDFMHLHKRPTLRKLKPDSMYETWEDDLDG 285
CASQ1_C_elegans EVQMRRPFEEDPLFAPTSADTEEEFEDWVEKNKEPVMQKLTLDNYFNLWRDPEEE 276
CASQ2_Homo_sapiens I.HIVAFAEKSDP..DGYEFLEILKQVARDNTD.NPDLSILWIDPDDFPLLVAYW 318
CASQ2_Canis_lupus_familiaris I.HIVAFAERSDP..DGYEFLEILKQVARDNTD.NPDLSIVWIDPDDFPLLVAYW 414
CASQ2_Mus_musculus I.HIVAFAEKSDP..DGYEFLEILKQVARDNTD.NPDLSILWIDPDDFPLLVAYW 318
CASQ2_Gallus_gallus I.HIVAFAEEDDP..DGFEFLEILKQVARDNTD.NPDLSIVWIDPDDFPLLITYW 318
CASQ2_Pelodiscus_sinensis I.HIVAFAEEDDP..DGFEFLEILKQVAKENTN.NPDLSIVWIDPDDFPLLITYW 316
CASQ1_H_sapiens I.HIVAFAEEADP..DGFEFLETLKAVAQDNTE.NPDLSIIWIDPDDFPLLVPYW 333
CASQ1_C_lupus_familiaris I.HIVAFAEEADP..DGFEFLETLKAVAQDNTD.NPDLSIIWIDPDDFPLLVPYW 333
CASQ1_M_musculus I.HIVAFAEEADP..DGYEFLETLKAVAQDNTE.NPDLSIIWIDPDDFPLLVPYW 333
CASQ1_X_tropicalis I.HIVAFAEEDDPDTDGYEFLEIIKEVAEDNTD.NPDLSIIWIDPEEFPLLIPYW 338
CASQ1_C_elegans ERMILAFVDEETR..EGRAMKRLLDKIADENSEHAGTLEIILVDPDEFPLMVDVW 329
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CASQ2_Homo_sapiens EKTFKIDLF.RPQIGVVNVTDADSVWMEIPD.......DDDLPTAEELEDWIEDV 365
CASQ2_Canis_lupus_familiaris EKTFKIDLF.KPQIGVVNVTDADSVWMEIPD.......DDDLPTAEELEDWIEDV 461
CASQ2_Mus_musculus EKTFKIDLF.KPQIGVVNVTDADSIWMEIPD.......DDDLPTAEELEDWIEDV 365
CASQ2_Gallus_gallus EKTFKIDLF.RPQIGIVNVTDADSVWMEIRD.......DDDLPTAEELEDWIEDV 365
CASQ2_Pelodiscus_sinensis EKTFKIDLF.KPQIGVVNVTDADSVWMEIMD.......DDDLPTAEELEDWIEDV 363
CASQ1_H_sapiens EKTFDIDLS.APQIGVVNVTDADSVWMEMDD.......EEDLPSAEELEDWLEDV 380
CASQ1_C_lupus_familiaris EKTFDIDLS.APQIGVVNVTDADSVWMEMDD.......EEDLPSAEELEDWLEDV 380
CASQ1_M_musculus EKTFDIDLS.APQIGVVNVTDADSIWMEMDN.......EEDLPSADELEDWLEDV 380
CASQ1_X_tropicalis EETFDIDLS.RPHIGIVNVTDADSVWMDMDD.......EEDLPTVDELEDWIEDV 385
CASQ1_C_elegans EDMFGIDIEEGPQIGLIDISEKEGIWFDMSQVNLDDPKKHSDSNFEALQSWIDQI 384
CASQ2_Homo_sapiens LSGKINTEDDDEDDDDDDNSDEEDND..DSDDDDDE.............. 399
CASQ2_Canis_lupus_familiaris LSGKINTEDDDNEEGDDGDDDEDDDD..DDGNNSDEESNDDSDDDDE... 506
CASQ2_Mus_musculus LSGKINTEDDDNEDEDDDGDDNDDDDDDDDDNDNSDEDNEDSDDDDDDDE 415
CASQ2_Gallus_gallus LSGKINTEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD......... 406
CASQ2_Pelodiscus_sinensis LSGKINTEDDDDDDDDDEDDDDDDDDDDDDDDDDDDD............. 400
CASQ1_H_sapiens LEGEINTEDDDDDDDD.................................. 396
CASQ1_C_lupus_familiaris LAGEINTEDDDEEEDDDDDDD............................. 401
CASQ1_M_musculus LEGEINTEDDDDDDDDDDDDDDDDD......................... 405
CASQ1_X_tropicalis LDGDINT........................................... 392
CASQ1_C_elegans LSGSISLDDDDDDEPEPPAPPPTPKGKKSRKE.....L............ 417
Figure S9: Multiple sequence alignment showing conservation across calsequestrins.
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Table S1: Crystallographic Data Collection and Refinement
Native (6OWV) Ytterbium-Complexed (6OWW)
Data Collection
Wavelength (A˚) 1.116 1.386
Space Group P 43 2 2 P 1 21 1
Cell Dimensions
a, b, c (A˚) 62.5329, 62.5329, 213.189 85.8318, 86.0152, 214.34
α,β,γ (◦) 90, 90, 90 90, 89.9072, 90
Resolution (A˚) 53.94 - 1.88 (1.947 - 1.88) 107.2 - 3.84 (3.977 - 3.84)
Rpim (%) 1.8 (194.8) 16.2 (85.0)
CC1/2 0.999 (0.422) 0.992 (0.616)
Mn(I)/σ(I) 14.82 (0.52) 4.52 (0.96)
Completeness (%) 97.76 (79.77) 98.45 (98.05)
Multiplicity 22.5 (12.6) 11.2 (11.5)
No. Unique Reflections 35501 (3425) 29897 (2924)
Refinement
Rwork / Rfree (%) 21.4 / 25.4 29.1 / 34.2
Resolution (A˚) 53.94 - 1.88 107.2 - 3.84
No. of chains in AU 1 8
Number of non-hydrogen atoms 2779 21752
Protein 2718 21665
Ligand 27 87
Solvent 34 N/A
B-Factors
Protein 81.93 97.36
Ligand 112.54 135.46
Solvent 55.84 N/A
R.m.s. deviations
Bond lengths (A˚) 0.009 0.008
Bond angles (◦) 1.25 1.14
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Table S2: Comparison of Crystallographic Space Group and Unit Cell Across All Published Calsequestrin Struc-
tures
PDB Code Year Protein Space Group Unit Cell Edges Unit Cell Angles
6OWV 2019 CASQ2 (Homo) P 43 2 2 62.52, 62.52, 213.15 90, 90, 90
1A8Y 1998 CASQ1 (Oryctolagus) C 2 2 21 59.740, 145.560, 111.790 90.00, 90.00, 90.00
1SJI 2004 CASQ2 (Canis) I 4 145.188, 145.188, 99.82 90, 90, 90
2VAF 2007 CASQ2 (Homo) I 41 2 2 150.650, 150.650, 227.470 90.00, 90.00, 90.00
3TRP 2012 CASQ1 (Oryctolagus) C 2 2 21 59.122, 144.863, 110.376 90.00, 90.00, 90.00
3TRQ 2012 CASQ1 (Oryctolagus) C 2 2 21 59.271, 144.565, 111.170 90.00, 90.00, 90.00
3UOM 2012 CASQ1 (Homo) P 1 89.799, 89.793, 119.161 90.13, 89.90, 60.05
3US3 2012 CASQ1 (Oryctolagus) C 2 2 21 59.214, 144.811, 110.471 90.00, 90.00, 90.00
3V1W 2012 CASQ1 (Oryctolagus) C 2 2 21 59.082, 144.592, 110.965 90.00, 90.00, 90.00
5CRD 2015 CASQ1 (Homo) C 2 2 21 59.170, 145.132, 110.242 90.00, 90.00, 90.00
5CRE 2015 CASQ1 (Homo) P 21 21 2 66.106, 82.815, 89.269 90.00, 90.00, 90.00
5CRG 2015 CASQ1 (Homo) P 1 21 1 91.179, 67.462, 158.062 90.00, 96.48, 90.00
5CRH 2015 CASQ1 (Homo) P 1 21 1 65.681, 68.553, 99.262 90.00, 92.84, 90.00
5KN0 2016 CASQ1 (Bos) P 1 60.342, 92.994, 101.849 71.12, 84.57, 73.48
5KN1 2015 CASQ1 (Bos) C 2 2 21 135.669, 165.604, 156.626 90.00, 90.00, 90.00
5KN2 2016 CASQ1 (Bos) C 2 2 21 130.363, 169.194, 155.477 90.00, 90.00, 90.00
5KN3 2016 CASQ1 (Bos) C 2 2 21 59.393, 146.060, 110.340 90.00, 90.00, 90.00
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Table S3: Comparison of buried surface area (BSA) at dimer interfaces across all published calsequestrin struc-
tures. All calsequestrin dimers observed to date have the same symmetry but can be divided into two classes
based on rigid body rotations of the chains (see Figure 5 for additional details).
PDB Code CASQ2/CASQ1 Packing BSA (A˚2) DeltaG
6OWV CASQ2 Tightly-Packed 2566.0 -29.2
1A8Y CASQ1 Loosely-Packed 2051.0 -25.0
1SJI CASQ2 Loosely-Packed 1815.0 -27.6
2VAF CASQ2 Tightly-Packed 2178.0 -25.4
3TRP CASQ1 Loosely-Packed 2201.0 -25.5
3TRQ CASQ1 Loosely-Packed 2326.0 -23.7
3UOM CASQ1 Tightly-Packed 2463.0 -24.5
3US3 CASQ1 Loosely-Packed 2174.0 -25.7
3V1W CASQ1 Loosely-Packed 2163.0 -25.6
5CRD CASQ1 Loosely-Packed 2190.0 -25.1
5CRE CASQ1 Loosely-Packed 2058.0 -25.3
5CRG CASQ1 Tightly-Packed 2447.0 -29.7
5CRH CASQ1 Tightly-Packed 2458.0 -30.9
5KN0 CASQ1 Loosely-Packed 2482.0 -23.3
5KN1 CASQ1 Tightly-Packed 2038.0 -22.7
5KN2 CASQ1 Tightly-Packed 2265.0 -28.1
5KN3 CASQ1 Loosely-Packed 2219.0 -23.4
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Table S4: Comparison of buried surface area (BSA) at putative dimer-dimer multimerization interfaces observed in
all published calsequestrin structures. Residues with buried surfaces area at a dimer-dimer interface are rendered
as spheres.
PDB Code CASQ2/CASQ1 Interface BSA (A˚2) Oriented View Equivalent PDBs1
6OWV CASQ2
Tetramer (BC) 734.0
6OWW
Tetramer (AC) 382.0
Tetramer (BD) 381.0
Tetramer (AD) 101.0
1A8Y CASQ1
Tetramer (BC) 715.0
3TRP, 3TRQ,
3US3, 3V1W,
5CRD, 5KN0,
5KN3
1SJI CASQ2
Tetramer (BC) 305.0
Tetramer (AC) 188.0
2VAF CASQ2
Tetramer (BC) 509.0
3UOM CASQ1
Tetramer (BC) 724.0
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. . . continued
PDB Code CASQ2/CASQ1 Interface BSA (A˚2) Oriented View Equivalent PDBs
5CRE CASQ1
Tetramer (BC) 255.0
Tetramer (AC) 162.0
5CRG CASQ1
Tetramer (AC) 304.0
Tetramer (BC) 74.0
5CRH CASQ1
Tetramer (AC) 102.0
5KN1 CASQ1
Tetramer (BC) 436.0
5KN2
1Where equivalent PDB codes are listed, space group and unit cell, and consequently interfaces, are isomor-
phous (with the exception of 5KN0, which contains a tetramer equivalent to 1A8Y, but the structure was determined
in P1).
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Table S5: Oligonucleotides used in this study.
Oligonucleotide Sequence
Primer to amplify H. sapiens CASQ2, forward ATGAAGAGAACTCACTTGTTTATTGT
Primer to amplify H. sapiens CASQ2, reverse CTATTCATCATCATCGTCATCACTGT
Primer to amplify H. sapiens CASQ2 with homol-
ogy tails for the pET28 vector, forward (skips signal
peptide sequence)
TTCCAGGGCCATATG GCTAGC AGGGCAGAA-
GAGGGGCTTA
Primer to amplify H. sapiens CASQ2 with homol-
ogy tails for the pET28 vector, reverse
CGGAGCTCGAATTC GGATCC CTATTCATCATCATCGT-
CATCACTGT
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D50A, forward
AAAGAAATATgccTTGCTTTGCC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D50A, reverse
AAAACCTGCTTGAAGTTCTTC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D144A, forward
CTAATTGAAGcCCCAGTGGAG
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D144A, reverse
ATCCAAGAGGAACTCCAC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, E174A, forward
TTCAAGAGTGccGACTCAGAATACTAC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, E174A, reverse
AAAGCCAATGAGTTTGATG
Primer for site-directed mutagenesis of H. sapiens
CASQ2, S173I, forward
CTTTTTCAAGattGAGGACTCAGAATAC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, S173I, reverse
CCAATGAGTTTGATGTAGTC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, K180R, forward
AGAATACTACcggGCTTTTGAAGAAGC
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. . . continued
Oligonucleotide Sequence
Primer for site-directed mutagenesis of H. sapiens
CASQ2, K180R, reverse
GAGTCCTCACTCTTGAAAAAG
Primer for site-directed mutagenesis of H. sapiens
CASQ2, E184A, forward
GCTTTTGAAGcAGCAGCTGAAC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, E184A, reverse
CTTGTAGTATTCTGAGTCC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, E187A on E184A background, forward
GCAGCAGCTGcACACTTCCAG
Primer for site-directed mutagenesis of H. sapiens
CASQ2, E187A on E184A background, reverse
TTCAAAAGCCTTGTAGTATTCTG
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D325I, forward
TTTCAAGATTatCCTATTCAGGCCACAG
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D325I, reverse
GTCTTCTCCCAGTAGGCA
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D348A, forward
GAGATTCCAGccGATGACGATCTTCC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D348A, reverse
CATCCAGACACTGTCAGC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D350A on D348A background, forward
CCAGCCGATGcCGATCTTCCA
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D350A on D348A background, reverse
AATCTCCATCCAGACACTG
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D351A, forward
GATGATGACGccCTTCCAACTGC
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. . . continued
Oligonucleotide Sequence
Primer for site-directed mutagenesis of H. sapiens
CASQ2, D351A, reverse
TGGAATCTCCATCCAGAC
Primer for site-directed mutagenesis of H. sapiens
CASQ2, E357A on D351A background, forward
ACTGCTGAGGccCTGGAGGACTG
Primer for site-directed mutagenesis of H. sapiens
CASQ2, E357A on D351A background, reverse
TGGAAGGGCGTCATCATC
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